Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Journal of Pharmacological and Toxicological Methods
|
August 7, 2013
Accelerated Caco-2 cell permeability model for drug discovery
E Sevin, L Dehouck, A Fabulas-da Costa, et al.
International Journal of Pharmaceutics
|
May 2, 2018
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment
M J Ramalho, E Sevin, F Gosselet, et al.
Gynecologic Oncology
|
September 24, 2009
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study
F Joly, T Petit, P Pautier, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 8, 1999
d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography
L J Siever, M S Buchsbaum, A S New, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
F Selle, E Sevin, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2013
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
C Falandry, B Weber, A-M Savoye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Journal of Pharmacological and Toxicological Methods
|
August 7, 2013
Accelerated Caco-2 cell permeability model for drug discovery
E Sevin, L Dehouck, A Fabulas-da Costa, et al.
International Journal of Pharmaceutics
|
May 2, 2018
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment
M J Ramalho, E Sevin, F Gosselet, et al.
Gynecologic Oncology
|
September 24, 2009
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study
F Joly, T Petit, P Pautier, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 8, 1999
d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography
L J Siever, M S Buchsbaum, A S New, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2014
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
F Selle, E Sevin, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2013
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial
C Falandry, B Weber, A-M Savoye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Page
of 2